BMS in the news

Novartis and Bristol Myers Squibb have paused autoimmune CAR-T therapy trials due to patient deaths and inflammatory events, prompting safety reviews and discussions about potential manufacturing links to side effects.

Bristol Myers Squibb ended its partnership with Cellares for CAR T-cell therapy production after Cellares' system failed to meet manufacturing standards for Breyanzi, leading to Cellares laying off about 100 employees.

BMS Holdings, a Malaysian retailer and distributor of tiles, stone surfaces, bathware, and kitchenware, reported strong Q4 FY2026 financial results with a significant increase in profit and revenue, and is expanding its market presence.

Bristol Myers Squibb is investing in NVIDIA DGX Vera Rubin systems to accelerate AI-driven research and development in drug discovery.

Tom Shortt, an engineering director at Bristol Myers Squibb (BMS), discusses his career path influenced by early farm machinery mechanics, his current role leading a multidisciplinary engineering team impacting medicine delivery, and his focus on site evolution, decarbonization, and digital innovation.

Bristol Myers Squibb's drug Krazati failed to meet primary endpoints in a confirmatory Phase 3 trial for metastatic colorectal cancer.

Current marine insurance market conditions offer lower rates and higher capacity due to increased competition, though this favorable period may be brief.

Global insurance broker BMS has launched a new capability centre in Mumbai to scale its AI, analytics, and technology operations.

BMS Group launched a global capability centre in Mumbai to scale up its data, AI, and insurance analytics operations.

A single marketer scaled production and expanded services into five new industrial sectors including healthcare and hospitality.

BMS established a dedicated delegated authority and consortia team to streamline Lloyd’s market capacity and portfolio management.

BMS Holdings Berhad has over 1 billion shares restricted from sale until the moratorium ends on June 8, 2026.

Political pressure is mounting to block biotech deals like the Bristol Myers Squibb and Jiangsu Hengrui partnership via the COINS Act of 2025.

Interim Phase 2 data show the bispecific drug pumitamig combined with chemotherapy effectively shrinks tumors in patients with advanced non-small cell lung cancer.

Bristol Myers Squibb received a state recommendation for tax breaks on a planned $1 billion manufacturing plant in Texas.

Political tension is rising as lawmakers move to restrict biotechnology deals with Chinese firms following the BMS-Hengrui licensing agreement.

A GOP chairman is pushing for restrictions on U.S. biotech investments in China, specifically targeting Bristol Myers Squibb's dealmaking.

Bristol Myers Squibb is evaluating a $1 billion manufacturing site in Houston's Generation Park that would employ 500 people.

Tempus AI and Bristol Myers Squibb are expanding their partnership to use AI and real-world data for oncology and neuroscience clinical trial design.

Tempus AI expanded its partnership with Bristol Myers Squibb to use AI and real-world data to improve oncology and neuroscience clinical trial success rates.